Global Pulmonary Drug Delivery Systems Market: Snapshot

Pulmonary drug delivery systems refer to the technologies that are used to treat diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis using pulmonary route of drug administration. While these systems have been in medical use for more than six decades, recent technological advancements in pulmonary drug delivery systems have expanded their potential application in other diseases as well including diabetes, lung cancer, and others. The market for pulmonary drug delivery systems is projected to be worth US$28.7 bn by the end of 2019, propagating at a notable CAGR of 4.4% during the forecast period of 2017 to 2019.

Apart from growing adoption of pulmonary drug delivery as an alternative to route of drug delivery, the market is gaining traction from some of the other factors such as the development of smart and digital inhalers, increasing number of smokers, and growth of the distribution network since the emergence of ecommerce. On the flip side, regulatory hurdles, patent expiration of some of the blockbuster drugs, and issues pertaining to the stability of drugs are some of the restraints hindering the prosperity of the global pulmonary drug delivery systems market. However, the vendors of this market are expected to gain vast new opportunities in the emerging economies of Asia Pacific.

global-pulmonary-drug-delivery-systems-market.jpg

Metered Dore Inhalers Market’s Key Product Segment

On the basis of product type, the pulmonary drug delivery devices market has been segmented into nebulizers, metered dose inhalers (MDI), and dry powder inhaler (DPI). As of 2017, the MDI segment has the maximum demand, providing for a revenue of US$14,512.7 mn. MDIs can be further classified into three categories based on the drugs delivered, namely metered dose inhalers with bronchodilators, corticosteroids, and a combination of both. However, patents of blockbuster drugs such as Advair HFA/Seretide Evohaler and Ventolin HFA/Ventolin Evohaler by GlaxoSmithKline have expired in 2017 and is expected to reflect negatively over the MDI segment. On the other hand, the demand for nebulizers and DPIs have been anticipated multiply profitably during the forecast period of 2017 to 2019.

The report also classifies the pulmonary drug delivery systems market on the basis of application, into COPD, cystic fibrosis, and asthama. The latter provided for a demand worth of US$16,085.9 mn in 2017 and is projected to remain most profitable over the course of next seven years. The analysts of the report have also bifurcated the market on the basis of distribution channel into hospital pharmacies, retail pharmacies, and ecommerce.

Developed and Developing Economies Driving Demand

In terms of region, North America, Europe, and Asia Pacific are the three regions of greatest potential. According to the analysts, the North America pulmonary drug delivery systems market was worth US$10,072.8 mn, gaining traction from factors such as strong prevalence of asthma, consistent focus of the government to reduce treatment costs, and escalating percentage of geriatrics in the U.S. The European market for pulmonary drug delivery systems, which was valued at US$7,059.0 mn in 2017, is driven by the countries of Germany, France, the U.K., Italy, and Spain. Some of the major factors responsible for this stunted growth in Europe include active penetration by generic makers and government austerity measures in key countries to reduce prices. Vastly populated region of Asia Pacific, driven by the emerging economies of China and India, is expected to generate demand for pulmonary drug delivery devices at a robust rate during the forecast period of this report.

AstraZeneca Plc, Novartis AG, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc, Merck & Co. Inc., and Teva Pharmaceutical Industries Ltd. are a few key players operating in the global pulmonary drug delivery systems market.

Global Pulmonary Drug Delivery Devices Market: Overview

This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.

This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered within the scope of the study. This section also provides the overall information and data analysis of the global pulmonary drug delivery devices market with respect to the leading market segments based on major products, key applications, distribution channels, and geographies.

Global Pulmonary Drug Delivery Devices Market: Segmentation

The global pulmonary drug delivery devices market has been studied based on major product type, application segments, major distribution channels, and regional as well as national markets. Based on product type, the global market has been categorized into three major segments: Dry Powder Inhalers, Metered Dose Inhalers and Nebulizers. Based on application, the global market has been categorized into four segments: Asthma, COPD, cystic fibrosis, and others. Based on distribution channels, the global market has been categorized into three key segments: retail pharmacies, hospital pharmacies, and e-commerce.

The market for these segments has been extensively analyzed based on their utility, effectiveness, sales, and geographic presence. Market revenue in terms of US$ Mn for the period from 2014 to 2019 along with the compound annual growth rate (CAGR %) from 2017 to 2019 are provided for all segments, considering 2016 as the base year.

The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the global pulmonary drug delivery devices market and could influence the market in the near future. Market attractiveness analysis has been provided in all the sections of the report in order to explain the intensity of competition in the market across different products / applications / distribution channels / geographies.

Global Pulmonary Drug Delivery Devices Market: Regional Analysis

Geographically, the pulmonary drug delivery devices market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). Each regional market for pulmonary drug delivery devices market has been further categorized into major product, application, and end-user segments considered within the scope of the study.

Key country (U.S., Japan, Germany, France, U.K., Australia, Canada, China, Brazil, Mexico, India, etc.) market revenues have also been provided in different regional sections within the report. Market revenue in terms of US$ Mn for the period from 2014 to 2019 along with CAGR % from 2017 to 2019 are provided for all the regions and nations considering 2016 as the base year.

Global Pulmonary Drug Delivery Devices Market: Competitive Outlook

The competitive scenario among different market players is evaluated through market share analysis in the competition landscape section of the pulmonary drug delivery devices market report. The section also includes competition matrix that analyzes the competition among some of the top global players operating in the market. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global pulmonary drug delivery devices market.

The report also profiles key players operating in the pulmonary drug delivery devices market based on various attributes such as company details, SWOT analysis, strategic overview, financials, and business overview. Major players profiled in this report include AstraZeneca plc, Novartis AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, 3M Healthcare, Omron Corporation, and others.